Overview

Safety Study of an Intravenous Staphylococcus Aureus Immune Globulin (Human), [Altastaph] in Low-Birth-Weight-Neonates

Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
The main objective will be to test the safety of two intravenous infusions of Altastaph, a human immunoglobulin product. The study will also test the ability of Altastaph to protect against S. aureus infection.
Phase:
Phase 2
Details
Lead Sponsor:
Nabi Biopharmaceuticals
Treatments:
Antibodies
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin